戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 able in risk stratification of patients with arterial occlusive disease.
2 scularization for lower extremity peripheral arterial occlusive disease.
3 9 years; range, 54-80 years) with peripheral arterial occlusive disease.
4 tic arteries of patients suspected of having arterial occlusive disease.
5 and economical assessment of lower extremity arterial occlusive disease.
6 d on the order of testing or the severity of arterial occlusive disease.
7 ively assess the severity of lower extremity arterial occlusive disease.
8 for the treatment of atherosclerotic carotid arterial occlusive disease.
9 tion of diagnosis of chronic lower-extremity arterial occlusive disease.
10  mechanism that protects against ischemia in arterial occlusive disease.
11 5% CI, 1.24-3.33]; P = .002), and peripheral arterial occlusive disease (adjusted HR, 2.15 [95% CI, 1
12                              Atherosclerotic arterial occlusive disease affecting the lower extremiti
13 alities may contribute to the development of arterial occlusive disease and associated clinical event
14  patients treated with dasatinib, peripheral arterial occlusive disease and other arterial disorders
15 s in patients suspected of having peripheral arterial occlusive disease, and diagnostic performance w
16                                              Arterial occlusive diseases are major causes of morbidit
17 tion procedure (aortoiliac and infrainguinal arterial occlusive disease) at VQI-participating centers
18 ity due to worsening pre-existing peripheral arterial occlusive disease in a patient who had received
19 dial flow changes associated with mesenteric arterial occlusive disease (MAOD) are unknown.
20 induced fatty liver, atrial thrombus, severe arterial occlusive disease of lower extremities, pleuro-
21 ng abdominal aortic aneurysm (33 percent) or arterial occlusive disease of the legs (67 percent).
22                                   Peripheral arterial occlusive disease (PAOD) accounts for significa
23  Intermittent claudication due to peripheral arterial occlusive disease (PAOD) is a common cause of p
24                   Lower extremity peripheral arterial occlusive disease poses a unique challenge to t
25 ls in 60 randomized patients with peripheral arterial occlusive disease referred for 64-section multi
26                                              Arterial occlusive disease was detected by reader 1 in 5
27                                              Arterial occlusive disease was detected by reader 2 in 4
28 mocysteine, which are frequently elevated in arterial occlusive disease, we hypothesized that folic a